

RECEIVED  
GENERAL FAX CENTER  
AUG 22 2007



Vertex Pharmaceuticals Incorporated  
130 Waverly Street • Cambridge, MA 02139-4242  
Tel. 617.444.6100 • Fax 617.444.6483  
<http://www.vrtx.com>

## FAX TRANSMISSION

To	USPTO - 571-273-8300
Examiner	Celia C. Chang
Group Art Unit	1625
From	Michael C. Badia
Date	August 22, 2007
Application No.	10/767,638
Attorney Docket No.	VPI/02-128 US
Total Pages	64

### Message or Comment

If any problems occur with this fax transmittal, please call (617) 444-6467 immediately.

RECEIVED  
CENTRAL FAX CENTER  
AUG 22 2007

Attorney Docket No.: VPI/02-128 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/767,638  
Confirmation No.: 5416  
Filing Date: January 29, 2004  
Examiner: Celia C. Chang  
Group Art Unit: 1625  
Applicants: Paul S. Charifson et al.  
For: GYRASE INHIBITORS AND USES THEREOF

Certificate of Facsimile Transmission Under 37 CFR §1.8

I hereby certify that this correspondence and any documents referred to as attached hereto are being facsimile transmitted to the United States Patent and Trademark Office on August 22, 2007.



Michael C. Badia

August 22, 2007  
Cambridge, Massachusetts

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Sir:

Transmitted herewith: [X] an Amendment and Reply to Office Action (including Exhibits A &B); [X] a Petition for Extension of Time; [X] a Supplemental Information Disclosure Statement; [ ] a Power of Attorney; [X] Declaration of Paul S. Charifson Under 37 C.F.R. § 1.132; [ ] a copy of a Notice to File Missing Parts; [ ] a Response to Notice to File Missing Parts; [ ] a Supplemental Declaration; [ ] an Associate Power of Attorney; [ ] a substitute Specification; [ ] formal drawings; [ ] Notice of Appeal; [ ] Appeal Brief; [ ] Petition for Revival; to be filed in the above-identified patent application.

RECEIVED  
CENTRAL FAX CENTER  
AUG 22 2007

Applicants: Paul S. Charifson et al.  
Application No.: 10/767,638

FEE FOR ADDITIONAL CLAIMS

- [X] A fee for additional claims is not required.
- [ ] A fee for additional claims is required.
- [ ] A check in the amount of \$\_\_\_\_ in payment of the filing fee is transmitted herewith.
- [ ] Please charge \$\_\_\_\_ to Deposit Account No. 50-0725 in payment of the filing fee. A duplicate copy of this transmittal letter is transmitted herewith.
- [X] The Director is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. § 1.16, in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

EXTENSION FEE


- [X] The following extension is applicable to the Response filed herewith; [ ] \$120.00 extension fee for response within first month pursuant to 37 C.F.R. § 1.136(a); [ ] \$450.00 extension fee for response within second month pursuant to 37 C.F.R. § 1.136(a); [X] \$1,020.00 extension fee for response within third month pursuant to 37 C.F.R. § 1.136(a); [ ] \$1,590.00 extension fee for response within fourth month pursuant to 37 C.F.R. § 1.136(a); [ ] \$2,160.00 within fifth month pursuant to 37 C.F.R. § 1.136(a).
- [ ] A check in the amount of [ ] \$120.00; [ ] \$450.00; [ ] \$1,020.00; [ ] \$1,590.00; [ ] \$2,160.00 in payment of the extension fee is transmitted herewith.
- [X] Please charge the extension fee in the amount of [ ] \$120.00; [ ] \$450.00; [X] \$1,020.00; [ ] \$1,590.00; [ ] \$2,160.00 to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.
- [X] The Director is hereby authorized to charge payment of any additional fees required under 37 C.F.R. § 1.17 in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 50-0725. A duplicate copy of this transmittal letter is transmitted herewith.

Applicants: Paul S. Charifson et al.  
Application No.: 10/767,638

MISCELLANEOUS FEES

[ ] Please charge \$ \_\_\_\_\_ to Deposit Account No. 50-0725 in payment of the  
for \_\_\_\_\_ (37 C.F.R. § \_\_\_\_\_.)

Respectfully submitted,

  
\_\_\_\_\_  
Michael C. Badia, Reg. No. 51,424  
Agent for Applicants  
c/o Vertex Pharmaceuticals Incorporated  
130 Waverly Street  
Cambridge, Massachusetts 02139  
Tel: (617) 444-6467  
Fax: (617) 444-6483